Why Are The Recoveries At Barclays PLC, AstraZeneca plc & Banco Santander SA Faltering?

Barclays PLC (LON: BARC), AstraZeneca plc (LON: AZN) and Banco Santander SA (LON: BNC) are heading down again.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Just when will our FTSE 100 banks finally make it back from the dead?

Look at Barclays (LSE: BARC), the one that famously didn’t need a government bailout during the crisis as it was still desirable enough to attract private capital. Barclays has faced its share of misbehaviour, with its part in the Libor-fixing scandal especially shameful. But the bank’s liquidity ratios have been improving and it looks set to easily satisfy regulatory requirements over the long term. And with earnings growth forecast this year and next, we’re looking at forward P/E ratios of only 10, dropping to 8.5 — and that’s with dividends set to yield 3% and growing.

But though the share price put in a good first half in 2015, since the end of July there’s been a 23% slump to 225p. The faltering economic outlook will surely have something to do with that, but this is surely an oversold share now, isn’t it?

Magic wearing off?

It’s not just banks. AstraZeneca (LSE: AZN) has been one of the hottest tipped companies in the recovery stakes for some time, and the shares were doing well. But since late April we’ve seen a 7% fall to 4,510p, and that’s even after an upward spike in the past couple of weeks. So what gives?

It may well be partly because Soriot fever has abated — new boss Pascal Soriot was the new broom that the pharmaceuticals giant desperately needed, and expectations were pushed high. But a return to sustainable growth was never on the cards before 2017, though you always get those who expect results to turn out better than expected.

With a flat year predicted this year followed by a 5% EPS fall in 2016, things are going as well as expected, but nothing more. The P/E is a little high at 16 to 17, but with dividends set to yield 4.1% we could be seeing a nice upwards re-rating when that growth does appear.

Eurozone misery

Banco Santander (LSE: BNC) has always seem a bit of a weird one to UK bank watchers, with its mad-looking dividend policy of paying out far more than it took in. It got away with that because the bulk of the bank’s Spanish shareholders would take scrip instead of cash — but you get nothing for nothing, and that increasingly dilutes each subsequent year’s earnings.

Still, up until the middle of 2014, the share price was recovering nicely — but since then there’s been a 40% reversal and the price is now down at 363p. Since Ana Botín assumed the chair after the death of her father Emilio, Santander has switched to a more standard dividend policy and this year’s payment has been slashed — so there’s some adjustment happening.

But Europe’s continuing woes are weighing heavily on the eurozone’s largest bank, and while the zone is still looking this sick I can see Santander shares remaining depressed.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Barclays. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »